HSP90 transmission-blocking vaccine

HSP90 transmission-blocking vaccine is a vaccine candidate designed to block the transmission of the malaria parasite, *Plasmodium*, by targeting heat shock protein 90 (HSP90) on the surface of female gametes. Developed through collaborative research involving Mercer University, the Johns Hopkins Bloomberg School of Public Health, and the National Institute of Allergy and Infectious Diseases (NIAID), the vaccine targets a critical step in the parasite's life cycle. During fertilization in the mosquito midgut, female gamete surface HSP90 acts as a key ligand for interaction with male gametes. Antibodies induced by the vaccine bind to HSP90, preventing fertilization and subsequent oocyst formation, thereby interrupting the transmission of malaria.

Other names

HSP90 malaria vaccineHSP-90 malaria vaccineHSP 90 malaria vaccineHSP90 TBVHSP-90 TBVHSP 90 TBVPlasmodium HSP90 transmission-blocking vaccine